Tuesday | Wednesday | Wednesday (OnDemand) | Thursday | Friday
WEDNESDAY, DECEMBER 9, 2020
     
     
8:45 am - 9:00 am WELCOME AND OPENING REMARKS
Carlos L. Arteaga, MD
UT Southwestern Medical Center
Simmons Comprehensive Cancer Center
Dallas, TX

Virginia G. Kaklamani, MD
UT Health San Antonio
San Antonio, TX

C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX
 
     
9:00 am - 12:00 pm

GENERAL SESSION 1

 
     
9:00 am GS1-01.  Final invasive disease-free survival analysis of monarchE: abemaciclib combined with adjuvant endocrine therapy for high risk early breast cancer
 
                           Rastogi P, Johnston S, Harbeck N, Toi M, O'Shaughnessy JA, Im Y-H, Reinisch M, Shao Z, Kellokumpu Lehtinen PL, Huang C-S, Tryakin A, Goetz M, Rugo HS, Senkus E, Testa L, Andersson M, Tamura K, Steger GG, Del Mastro L, Cox J, Forrester T, Sherwood S, Li X, Wei R, Martin M. University of Pittsburgh, Pittsburgh, PA; Royal Marsden NHS Foundation Trust, London, United Kingdom; Breast Center, Ludwig-Maximilians-Universität München (LMU), Munich, Germany; Kyoto University Hospital, Kyoto, Japan; Texas Oncology, Dallas, TX; Samsung Medical Center, Seoul, Republic of Korea; Brustzentrum Kliniken Essen-Mitte, Essen, Germany; Fudan University Shanghai Cancer Center, Shanghai, China; Tampere University Hospital TAYS, Tampere, Finland; National Taiwan University Hospital, Taipei, Taiwan; N.N.Blokhin Russian Cancer Research Center, Moscow, Russian Federation; Mayo Clinic, Rochester, MN; UCSF, San Francisco, CA; Medical University of Gdansk, Gdansk, Poland; Clinica Onco Star, Sao Paulo, Brazil; Rigshospitalet, Copenhagen, Denmark; National cancer Center Hospital, Tokyo, Japan;  Medical University of Vienna, Vienna, Austria; Breast Unit, IRCSS Ospedale Policlinico, Università di, Genova, Italy; Eli Lilly and Company, Indianapolis, IN; Hospital General Universitario Gregorio Marañon, Madrid, Spain.  
     
9:00 am

GS1-04. 

 
                          
 
 
9:15 am GS1-02. Phase III study of palbociclib combined with endocrine therapy (ET) in patients with hormone-receptor-positive (HR+), HER2-negative primary breast cancerand with high relapse risk after neoadjuvant chemotherapy (NACT): First results from PENELOPE-B  
  Loibl S, Marmé F, Martin M, Untch M, Bonnefoi H, Kim S-B, Bear H, Mc Carthy N, Melé Olivé M, Gelmon K, García Sáenz J, Kelly CM, Reimer T, Toi M, Rugo HS, Seiler S, Nekljudova V, Denkert C, Gnant M, Makris A, Burchardi N, von Minckwitz G. German Breast Group, Neu-Isenburg, Germany; UMM-Universitäsklinikum Mannheim, Mannheim, Germany; Instituto de Investigacion Sanitaria Gregorio Marañon, CIBERONC, Universidad Complutense, Madrid, Spain; Helios Kliniken Berlin-Buch, Berlin, Germany; Institut Bergonié and Université de Bordeaux INSERM U916, Bordeaux, France; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; Division of Surgical Oncology, Massey Cancer Center, Virginia Commonwealth University, VCU Health, Richmond, VA; Breast Cancer Trials Australia and New Zealand and University of Queensland, Queensland, Australia; Oncology research group, Hospital Universitario Sant Joan de Reus, Reus, Spain; BC Cancer Agency, Vancouver, BC, Canada; Service de Oncología Médica, Hospital Clínico San Carlos, Madrid, Spain; Breast Group, Cancer Trials Ireland, Dublin, Ireland; Department of Obstetrics and Gynecology, University of Rostock, Rostock, Germany; Breast Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Breast Department, UCSF Helen Diller Family Comprehensive Cancer Center, San Franscisco, CA; Institut für Pathologie Philipps-Universität Marburg, Marburg, Germany; Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Mount Vernon Cancer Centre, Northwood, United Kingdom.  
     
 9:30 am GS1-04. Correlative biomarker analysis of intrinsic subtypes and efficacy across the MONALEESA Phase III studies  
  Prat A, Chaudhury A, Solovieff N, Paré L, Martinez D, Chic N, Martínez-Sáez O, Brasó-Maristany F, Rodriguez Lorenc K, Taran T, Babbar N, Su F. Hospital Clinic, SOLTI Breast Cancer Research Group, Translational Genomics and Targeted Therapies in Solid Tumors, Institut D’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Novartis Institutes for Biomedical Research, Boston, MA; SOLTI Breast Cancer Research Group, Translational Genomics and Targeted Therapies in Solid Tumors, Institut D’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Translational Genomics and Targeted Therapies in Solid Tumors, Institut D’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Novartis Pharmaceuticals, East Hanover, NJ; Novartis Pharma AG, Basel, Switzerland.
 
     
9:45 am

GS1-05. Hotspot ESR1 mutations rewire cell-cell adhesome to facilitate breast cancer metastasis

 
                          

Li Z, Wu Y, Bahreini A, Chen J, Qin Y, Levine KM, Tasdemir N, Priedigkeit N, Zhu L, Tseng GC, Jiang Y, Troness B, Buluwela L, Ali S, Arnesen S, Gertz J, Park BH, Zhang Q, Gerratana L, Davis A, Atkinson JM, El-Ashry D2, Cristofanilli M, Lee AV; Oesterreich S. University of Pittsburgh, Pittsburgh, PA; University of Minnesota, Minneapolis, MN; Imperial College London, London, United Kingdom; University of Utah, Salt Lake City, UT; Vanderbilt University, Nashville, TN; Northwestern University, Chicago, IL

.
 
     
10:00 am GS1-06. FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer
 
  Alberto Servetto1, Rahul Kollipara1, Luigi Formisano2, Chang-Ching Lin1, Kyung-min Lee1, Dhivya R Sudhan1, Ariella B Hanker1, Sumanta Chatterjee1, Angel Guerrero-Zotano3, Paula Gonzalez-Ericsson4, Saurabh Mendiratta1, Hiroaki Akamatsu1, Nicholas James5, Ralf Kittler1 and Carlos L Arteaga1. 1UT Southwestern Medical Center, Dallas, TX;2University of Naples "Federico II", Naples, Italy3Instituto Valenciano de Oncología, Valencia, Spain4Vanderbilt-Ingram Cancer Center, Nashville, TN;5University of Hawaii at Manoa, Manoa, HI.  
     
10:15 am GS1-07.  Treatment persistence of residual breast tumors through an embryonic diapause-like cancer cell state with suppressed Myc activity
 
                           Dhimolea E, De Matos Simoes R, Kansara D, Bouyssou J, Roth J, Sheffer M, Jeselsohn R, Gray N, Steidl U, Bartholdy B, Brown M, Culhane A, Mitsiades C. Dana Farber Cancer Institute, Boston, MA; Broad Institute of MIT and Harvard, Boston, MA; Albert Einstein College of Medicine, New York, NY.  
     
 10:30 am GS1-08 The MYC Oncogene Suppresses Tumor Immune Infiltration and Function which is Reversible with Combinatorial Immunotherapies.  
  Lee JV, Housley F, Yau C, Hemmati G, Zhang Y, Samson S, Baas C, Rugo H, Matloubian M, Goga A. UCSF, San Francisco, CA; National Cancer Institute, Bethesda, MD.  
     
 10:45 am GS1-09    
 
 
     
 11:00 am GS1-10   
 
 
     
10:00 am - 3:00 pm Exhibits  
     
11:30 am - 1:00 pm  CAREER DEVELOPMENT FORUM, sponsored by Eisai, Inc.
 
 
1:00 pm - 4:00 pm

GENERAL SESSION 2

 
1:00 pm GS2-01. The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ  
                          

Harismendy O, Nachmanson D, Evans MF, Mori H, Officer A, Yau C, Steward J, Yao H, O'Keefe T, Hasteh F, Stein GS, Jepsen K, Campbell M, Weaver DL, Hirst GL, Sprague BL, Esserman LJ, Gordon JA, Borowsky A, Stein JL. UC San Diego, San Diego, CA; University of Vermont, Burlington, VT; UC Davis, Davis, CA; UC San Francisco, San Francisco, CA.

 
     
1:15 pm GS2-02. 12 year results of anastrozole versus tamoxifen for the prevention of breast cancer in postmenopausal women with locally excised ductal carcinoma in-situ  
  Sestak I, Cuzick J, Bonanni B, Bundred N, Levy C, Loib S, Neven P, Stierer M, Holcombe C, Coleman R, Forbes J, Howell A. Centre for Cancer Prevention, London, United Kingdom; Istituto Europeo di Oncologia, Milan, Italy; University of Manchester, Manchester, United Kingdom; Centre François Baclesse, Caen, France; German Breast Group, Frankfurt, Germany; UZ Leuven, Leuven, Belgium; Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria; Royal Liverpool University Hospital, Liverpool, United Kingdom; University of Sheffield, Sheffield, United Kingdom; Breast Cancer Trials, Newcastle, Australia.  
     
3:45 pm GS2-03. Prime 2 randomised trial (postoperative radiotherapy in minimum-risk elderly): wide local excision and adjuvant hormonal therapy +/- whole breast irradiation in women =/> 65 years with early invasive breast cancer:10 year results
 
  Kunkler IH, Williams LJ, Jack W, Cameron DA, Dixon M. University of Edinburgh, Institute of Genetics and Molecular Medicine, United Kingdom; Usher Institute, Edinburgh University, Edinburgh, United Kingdom; Western General Hospital, Edinburgh, United Kingdom.  
     
4:00 pm  GS2-04. A randomized phase III study of radiation doses and fractionation schedules in non-low risk ductal carcinoma in situ (DCIS) of the breast (BIG 3-07/TROG 07.01)
 
  Chua B. UNSW Sydney and Prince of Wales Hospital, Sydney, Australia.  
     
 4:15 pm GS2-05 Genome-wide association study identifies UACA as a modulator of breast cancer chemoresistance and survival  
  Kushi LH, Zhu Q, Schultz E, Long J, Roh JM, Valice E, Laurent CA, Yan L, Ergas IJ, Davis W, Ranatunga DK, Kwan ML, Bao P-P, Zheng W, Shu X-O, Ambrosone CB, Yao S. Kaiser Permanente Northern California, Oakland, CA; Roswell Park Comprehensive Cancer Center, Buffalo, NY; Vanderbilt University Medical Center, Nashville, TN; Shanghai Municipal Center for Disease Prevention and Control, Shanghai, China.   
     
4:30 pm GS2-06. Exploring the causal role of the Human Gut Microbiome in Breast Cancer Risk using Mendelian Randomization  
                           Gavilá J, Saura C, Pascual T, Hernando C, Muñoz M, Paré L, González Farré B, Fernandez P, Galván P, González Farré X, Oliveira M, Gil Gil M, Arumi M, Ferrer Tur N, Montaño A, Izarzugaza Y, Llombart Cussac A, Bratos R, González S, Martínez E, Hoyos S, Rojas B, Virizuela JA, Ortega V, López R, Céliz P, Ciruelos E, Villagrasa P, Prat A.  Instituto Valenciano de Oncología, Valencia, Spain; Vall d' Hebron University Hospital, Barcelona, Spain; Hospital Clinic, Barcelona, Spain; Hospital Clínico Universitario de Valencia, Valencia, Spain; SOLTI Breast Cancer Research Group, Barcelona, Spain; Hospital General de Catalunya, Barcelona, Spain; Institut Catala d’ Oncologia Hospitalet, Hospitalet de Llobregat, Spain; Hospital Universitari Son Espases, Palma de Mallorca, Spain; Hospital Universitario Virgen del Rocío, Sevilla, Spain; Hospital Universitario Fundación Jimenes Díaz, Madrid, Spain; Hospital Universitario Arnau de Vilanova, Valencia, Spain; Centro Oncológico Internacional MD Anderson, Madrid, Spain; Hospital San Pedro de Alcántara, Cáceres, Spain; Consorcio Hospitalario Provincial de Castellón, Castellón de la Plana, Spain; Hospital Rey Juan Carlos, Madrid, Spain; Centro Integral Oncológico Clara Campal, Madrid, Spain; Hospital Virgen Macarena, Sevilla, Spain; Fundación Privada Asil de Granollers, Barcelona, Spain; Complejo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain; Hospital 12 de Octubre, Madrid, Spain.  
     
4:45 pm GS2-07. Glycemic Index, Glycemic Load and breast cancer risk: results from the prospective NutriNet-Santé cohort
  Debras C, Chazelas E, Srour B, Julia C, Kesse-Guyot E, Zelek L, Agaësse C, Druesne-Pecollo N, Galan P, Hercberg S, Latino-Martel P, Deschasaux M, Touvier M. Nutritional epidemiology Research Team (Inserm, Inra, Cnam, Paris 13 University), Bobigny, France; Oncology Department, Avicenne Hospital, AP-HP, Bobigny, France.  
     
4:00 pm - 5:00 pm

SPOTLIGHT SESSION 1: Novel Therapeutics

 
                          
 
5:00 pm - 6:00 pm SPOTLIGHT SESSION 2: Refining Targeted Therapy in HR+ Disease
 
     
6:00 pm - 7:00 pm SPOTLIGHT SESSION 3: Advances in HER2 Positive Disease
 

   
7:00 pm - 7:15 pm SPOTLIGHT SESSIONS - Live Q&A with the Spotlight Chairs and Spotlight Discussants  
     
7:30 pm - 9:30 pm

OPEN SATELLITE EVENTS 

 
     
 
Tuesday | Wednesday | Wednesday (OnDemand) | Thursday | Friday
 

S1-04.

S1-04.

Phase III study of trastuzumab emtansine (T-DM1) vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy including trastuzumab: primary results from KATHERINE
Limited to 200 participants; registrations will be accepted on a first-come, first-served basis and are free of charge. Badges are required and will be scanned at door for registration.   Attendees should prepare to visit 3-4 tables during the session. Attendees will be asked to rotate tables every 20 minutes.
Limited to 200 participants; registrations will be accepted on a first-come, first-served basis and are free of charge. Badges are required and will be scanned at door for registration.   Attendees should prepare to visit 3-4 tables during the session. Attendees will be asked to rotate tables every 20 minutes.
Limited to 200 participants; registrations will be accepted on a first-come, first-served basis and are free of charge. Badges are required and will be scanned at door for registration.   Attendees should prepare to visit 3-4 tables during the session. Attendees will be asked to rotate tables every 20 minutes.
Tuesday | Wednesday | Wednesday (OnDemand) | Thursday | Friday
In collaboration with  Astro     and     SSO